Skip to content

Cancer News & Analysis

14 articles

Market Mood

4 Bullish10 Neutral0 Bearish
Sellas Leukemia Vaccine Shows 9-Month Survival Benefit in Trial
EarningsBullish11/18/2026

Sellas Leukemia Vaccine Shows 9-Month Survival Benefit in Trial

Sellas Life Sciences reported that its experimental vaccine for acute myeloid leukemia (AML) achieved a 9-month survival benefit in a late-stage clinical trial. The vaccine reduced the risk of death in people with blood cancer, marking a significant development in cancer immunotherapy. This improved survival is a key milestone supporting the vaccine's effectiveness. The trial results come amid a notable year for breakthroughs in cancer drugs. Sellas' vaccine directly addresses AML, a serious and often deadly form of leukemia. Multiple reputable sources, including Memorial Sloan Kettering Cancer Center and Reuters, confirmed the survival improvement demonstrated by the vaccine in the clinical setting. This advancement could influence cancer treatment approaches and investor interest in oncology biotechs. The 9-month survival extension is concrete evidence of clinical benefit, which could affect future approvals and commercial potential for Sellas. For investors, the improved survival rate is a key factor that might impact the company's prospects and stock performance.

Read More: Sellas Leukemia Vaccine Shows 9-Month Survival Benefit in Trial
Astellas Secures Option for Audax Cancer Drug DAX-044
M&ANeutral10/27/2026

Astellas Secures Option for Audax Cancer Drug DAX-044

Astellas has obtained an option to license Audax's cancer drug DAX-044. The agreement gives Astellas the right to develop and commercialize the drug, which targets cancer treatment. This option deal marks a key strategic move by Astellas to expand its oncology pipeline. The specific financial terms or timeline of the option agreement were not disclosed in the article. DAX-044 is intended for the treatment of cancer, although the article does not specify the exact cancer types or clinical trial stages. This move reflects Astellas' focus on acquiring novel cancer therapies from smaller biotech companies like Audax. For investors, this option deal could signal potential future revenue growth for Astellas if DAX-044 advances through development and commercialization. The option agreement also highlights ongoing partnerships between major pharmaceutical companies and biotechs to bring innovative drugs to market.

Read More: Astellas Secures Option for Audax Cancer Drug DAX-044
GSK Cancer Drug Clears Rectal Tumours in 76% of Patients in Trial
EarningsBullish10/26/2026

GSK Cancer Drug Clears Rectal Tumours in 76% of Patients in Trial

GlaxoSmithKline's (GSK) cancer drug achieved a 76% clearance rate of rectal tumours in patients during a clinical trial. This result indicates a significant effect of the drug on tumour reduction in the studied group. The 76% clearance figure highlights the drug's potential therapeutic efficacy in rectal cancer treatment, based on the trial data. Although detailed trial design or patient numbers are not provided, this clearance metric is a key outcome. This development matters because it shows GSK's ongoing progress in cancer drug research. The reported tumour clearance rate could impact future regulatory decisions and investment in GSK's oncology pipeline, influencing company valuation based on clinical success.

Read More: GSK Cancer Drug Clears Rectal Tumours in 76% of Patients in Trial
NovaBridge Reports Phase 1b Gastric Cancer Drug Data
EarningsNeutral10/25/2026

NovaBridge Reports Phase 1b Gastric Cancer Drug Data

NovaBridge released data from its Phase 1b clinical trial for a gastric cancer drug. The report focuses on early patient responses and safety profiles without specifying exact figures. This phase assesses the drug's initial impact on cancer patients and monitors side effects to guide further development stages. Phase 1b trials are crucial as they determine dosage and initial efficacy signals before advancing to larger trials. NovaBridge's update indicates progress but does not include detailed statistics on patient outcomes or side effects. Observers await more comprehensive data in coming trial phases. This development matters because early trial results influence investment and partnership decisions. The company's ability to proceed successfully affects its valuation and future revenue potential from the drug. Investors will watch for more detailed efficacy and safety results in future reports to assess the drug’s commercial viability.

Read More: NovaBridge Reports Phase 1b Gastric Cancer Drug Data
Takeda (TAK) Reports Positive Phase 3 Trial Results for Gastric Cancer Drug
EarningsBullish10/23/2026

Takeda (TAK) Reports Positive Phase 3 Trial Results for Gastric Cancer Drug

Takeda Pharmaceutical Company (TAK) announced positive results from its phase 3 clinical trial for a new drug targeting gastric cancer. The trial showed significant effectiveness in improving patient outcomes compared to the standard treatment. The company did not disclose exact numerical data or specific efficacy percentages but confirmed the trial met its primary endpoints. Takeda plans to use these results to seek regulatory approvals and move closer to commercializing the therapy. This development is crucial as it could lead to a new treatment option for gastric cancer patients. For investors, the trial's success potentially increases the future revenue streams and clinical portfolio strength of Takeda. Upcoming regulatory decisions based on this data will be important to watch.

Read More: Takeda (TAK) Reports Positive Phase 3 Trial Results for Gastric Cancer Drug
Moderna (MRNA) Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
EarningsNeutral10/23/2026

Moderna (MRNA) Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%

Moderna (MRNA) and Merck reported that their experimental mRNA vaccine reduced the risk of melanoma recurrence by 42%. The vaccine targets the deadliest form of skin cancer, marking a significant development in cancer treatment. This data was shared widely on social media, impacting Moderna's stock performance. Following the release of the melanoma vaccine data, Moderna's stock experienced a sharp decline, breaking its record rally that had taken place in August. The drop reflects market concern over the leaked results and their implications. The exact figures on the stock's decline were not provided in the article. This vaccine development matters because it represents a potential new tool to reduce recurrence of melanoma, which has a high mortality rate. For investors, the 42% reduction in recurrence risk is a key figure, but the market’s reaction shows sensitivity to how such clinical data is released. It may affect Moderna's revenue prospects if further studies confirm vaccine efficacy and regulatory approvals follow.

Read More: Moderna (MRNA) Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
Moderna (MRNA) Cancer Vaccine Cuts Melanoma Risk by 42% in Trial
EarningsNeutral10/22/2026

Moderna (MRNA) Cancer Vaccine Cuts Melanoma Risk by 42% in Trial

Moderna's (MRNA) experimental cancer vaccine demonstrated a 42% reduction in the risk of melanoma recurrence or death after two years. This result highlights the vaccine's potential as a significant advancement for melanoma patients. Despite the positive trial outcome, the stock price fell following an embargo breach, suggesting investors reacted negatively to the timing or disclosure of the news. The vaccine's impact on long-term patient survival and cancer treatment remains under observation. This development matters because it represents a potentially effective cancer therapy, but investor reaction shows sensitivity to news delivery and confidentiality breaches. The 42% risk reduction is the key figure indicating vaccine effectiveness.

Read More: Moderna (MRNA) Cancer Vaccine Cuts Melanoma Risk by 42% in Trial
Moderna (MRNA) to Reveal mRNA Cancer Vaccine Data Next Month
TechNeutral9/21/2026

Moderna (MRNA) to Reveal mRNA Cancer Vaccine Data Next Month

Moderna (MRNA) is set to disclose data regarding its mRNA cancer vaccine next month. Analysts and medical professionals are seeking this information to assess the effectiveness of the personalized treatment. The upcoming data release could provide insights into the vaccine's performance and potential impact on the cancer treatment landscape. This matters for investors as it could influence decisions regarding Moderna's future revenue potential driven by novel therapies.

Read More: Moderna (MRNA) to Reveal mRNA Cancer Vaccine Data Next Month
Moderna (MRNA) Rises 9% After Phase 3 Melanoma Study Symposium Slot
EarningsBullish9/21/2026

Moderna (MRNA) Rises 9% After Phase 3 Melanoma Study Symposium Slot

Moderna (MRNA) shares surged 9% to $168 after its Phase 3 melanoma vaccine study was selected for the Presidential Symposium slot at the European Society for Medical Oncology congress on October 24. Meanwhile, Merck (MRK) gained 1% and BioNTech (BNTX) increased 2%. The selection highlights the significance of the study, although no new efficacy data was released. This offers a signal to investors that the research may lead to practice-changing developments in cancer treatment, impacting Moderna's evaluation and future opportunities.

Read More: Moderna (MRNA) Rises 9% After Phase 3 Melanoma Study Symposium Slot
Zipalertinib Trial Meets Endpoint in Lung Cancer Study
HealthNeutral8/12/2026

Zipalertinib Trial Meets Endpoint in Lung Cancer Study

Zipalertinib has met its primary endpoint in a clinical trial for lung cancer, indicating efficacy in treating this form of cancer. The success of this trial could impact future treatments and market confidence in Zipalertinib's potential. This development is vital as it showcases advances in oncology that investors and healthcare sectors monitor closely. For investors, the performance of Zipalertinib may influence related biotech stocks and innovation in cancer treatment.

Read More: Zipalertinib Trial Meets Endpoint in Lung Cancer Study
Moderna (MRNA) Stock Up 146% Year to Date Amid Market Rotation
MarketsNeutral7/4/2026

Moderna (MRNA) Stock Up 146% Year to Date Amid Market Rotation

Moderna, Inc. (NASDAQ: MRNA) is currently the 12th best-performing stock in the S&P 500, with a year-to-date gain of 146%. Despite this substantial increase, the company is still not profitable and does not expect to reach cash break-even until 2028, with earnings per share expected to turn positive only by 2029. This performance follows a period of stagnation post-COVID. Analysts highlight that while Moderna has promising prospects in cancer trials, investors are advised to wait for a pullback before buying, given the stock's significant rise.

Read More: Moderna (MRNA) Stock Up 146% Year to Date Amid Market Rotation
Grail (GRAL) Cancer Test Moves Closer to FDA Approval After Trials
EarningsNeutral6/21/2026

Grail (GRAL) Cancer Test Moves Closer to FDA Approval After Trials

Grail (NASDAQ: GRAL) recently reported a decline of over 30% in its stock price in 2026 following a failed primary endpoint in its NHS-Galleri trial aimed at early cancer detection. However, recovery of approximately 18.4% has occurred as investors consider the potential for FDA approval and medical coverage for its Galleri test, which can detect over 50 cancers. Grail emphasizes the importance of 12-month follow-up data to better demonstrate the test's efficacy. The case for the test remains focused on improving patient outcomes and reducing treatment costs associated with late-stage cancers.

Read More: Grail (GRAL) Cancer Test Moves Closer to FDA Approval After Trials
Zai Lab (ZLAB) and Amgen (AMGN) Collaborate on Lung Cancer Therapy
M&ANeutral4/19/2026

Zai Lab (ZLAB) and Amgen (AMGN) Collaborate on Lung Cancer Therapy

Zai Lab (ZLAB) and Amgen (AMGN) have announced a partnership to evaluate a combination therapy for lung cancer. This collaboration is aimed at improving treatment options for patients and could signify advancements in oncology therapies. The outcomes of this evaluation may impact both companies' stock performance and the broader market perception of lung cancer treatments. Investors will be watching the developments closely given the increasing focus on cancer therapies within the biopharmaceutical sector.

Read More: Zai Lab (ZLAB) and Amgen (AMGN) Collaborate on Lung Cancer Therapy
OpenAI Leadership Changes Announced Amid Medical Leaves for Executives
TechNeutral4/3/2026

OpenAI Leadership Changes Announced Amid Medical Leaves for Executives

Fidji Simo, OpenAI's product lead, is taking a medical leave due to Postural Orthostatic Tachycardia Syndrome (POTS) and has announced leadership changes. Simo joined OpenAI in May and cited her health condition's worsening, necessitating several weeks off. In her absence, OpenAI President Greg Brockman will oversee product, with Denise Dresser taking on additional responsibilities. Additionally, Kate Rouch, the marketing chief, is stepping down to focus on her late-stage breast cancer recovery, indicating significant transitions within OpenAI's leadership team.

Read More: OpenAI Leadership Changes Announced Amid Medical Leaves for Executives